With stints at the likes of Genzyme, Bayer and, most recently, TranScrip Partners, Gilbert Wagener, MD, PhD, is now signing up to UK biotech Rexgenero.

As senior vice president and chief medical officer, a new role for the company, Wagener will be tapped to lead cell therapy development, clinical and medical activities, and regulatory strategy.

Rexgenero is currently working on an late-stage cell therapy, known as REX-001, for critical limb ischemia (CLI) that causes burning pain in the feet as a result of blocked arteries in the lower limbs. Source: Fierce Biotech 2/7/2020